Misconceptions stymie HIV vaccine trials

University of Toronto researchers surveyed people at risk of contracting HIV and found that misconceptions about the safety of HIV vaccine trials are slowing research efforts. Along with a general distrust of medical professionals, the researchers found that many individuals believe participating in a vaccine trial could cause them to contract HIV, "as well as confusion over why HIV vaccine trials specifically target people in at-risk communities." Additionally, some survey participants expressed satisfaction with currently available HIV management drugs and felt that new therapies weren't crucial. Release

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.